LivaNova (LIVN) risk factors, FY2024 10-K

Risks Relating to the Company’s Business and Operations

1. 01LivaNova is subject to the risks of conducting business internationally
2. 02Reductions and interruptions in LivaNova’s supply chain have had, and may continue to have, adverse effects on LivaNova’s business, results of operations, cash flows, and financial condition
3. 03Cybersecurity incidents or other disruptions to LivaNova’s information technology systems could lead to reduced revenue, increased costs, liability claims, regulatory fines, litigation, harm to LivaNova’s competitive position, and loss of reputation
4. 04expensive to obtain, and LivaNova cannot be certain that the Company’s current levels of insurance will be available in the future on economically reasonable terms
5. 05The global medical device industry is highly competitive, and LivaNova may be unable to compete effectively
6. 06LivaNova’s research and development efforts rely upon investments and investment collaborations, and the Company cannot guarantee that any previous or future investments or investment collaborations will be successful
7. 07The continuing development of many of LivaNova’s products depends upon the Company maintaining appropriate working relationships with healthcare professionals
8. 08Quality issues with LivaNova’s processes, products, and services could harm the Company’s reputation for producing high-quality products and erode LivaNova’s competitive advantage, revenue, and market share
9. 09If LivaNova’s marketed medical devices are defective or otherwise pose safety risks, the FDA and similar non-U.S. governmental authorities could require their recall or initiate an enforcement action, or LivaNova may initiate a recall of the Company’s products or stop sales of products voluntarily
10. 10Failure to comply with product-related government regulations may materially adversely affect LivaNova’s business, results of operations, cash flows, and financial condition
11. 11LivaNova’s success depends on its employees and the Company’s ability to attract and retain key personnel needed to successfully operate its business, plan for future executive transitions, and negotiate with local works councils
12. 12LivaNova’s products are subject to complex laws and regulations, and failure to obtain product approvals, clearance, or reimbursement may materially adversely affect LivaNova’s business, results of operations, cash flows, and financial condition
13. 13The impact of pending or existing climate change may have a material impact to LivaNova’s future operations
14. 14Global healthcare policy changes may have a material adverse effect on LivaNova’s business, results of operations, financial condition, and cash flows
15. 15Failure to comply with anti-bribery laws could materially adversely affect LivaNova’s business and result in civil and/or criminal sanctions
16. 16If LivaNova’s business development and restructuring activities are unsuccessful, the Company may not realize the intended benefits
17. 17LivaNova may incur impairments of intangible assets, goodwill, and other long-lived assets that may adversely affect the Company’s financial results
18. 18Public health crises have had, and may continue to have, an adverse effect on LivaNova’s business, results of operations, cash flows, and financial condition, the nature and extent of which are uncertain and unpredictable

Legal, Regulatory, and Compliance Risks

1. 19As a manufacturer of medical devices, LivaNova is exposed to product liability claims that could adversely affect its consolidated financial condition and tarnish the Company’s reputation
2. 20Company’s technology, and may limit LivaNova’s competitive advantage. Third parties could obtain patents that may require LivaNova to negotiate licenses to conduct business, and the required licenses may not be available on reasonable terms or at all
3. 21Inadequate funding for U.S. federal government agencies and government shutdowns could negatively affect LivaNova’s business, results of operations, cash flows, and financial condition

Risks Related to LivaNova’s Indebtedness

1. 22Any failure by LivaNova to make required payments in respect of its indebtedness (after any applicable grace period) would constitute an event of default in respect of such indebtedness
2. 23The conditional exchange or conversion features of the 2025 Notes and 2029 Notes, as applicable, if triggered, may adversely affect LivaNova’s liquidity and operating results
3. 24The arbitrage or hedging strategy by purchasers of the 2025 Notes and 2029 Notes and Option Counterparties in connection with LivaNova’s 2025 Capped Calls and 2029 Capped Calls may affect the value of LivaNova’s ordinary shares
4. 25The Option Counterparties are financial institutions, and LivaNova is subject to the risk that they might default under the 2025 Capped Calls and 2029 Capped Calls. LivaNova’s exposure to the credit risk of the Option Counterparties is not secured by any collateral

Risks Relating to Tax and LivaNova’s Jurisdiction of Incorporation

1. 26LivaNova is incorporated in England and Wales and governed by their laws, which may afford less protection to shareholders than under U.S. laws
2. 27Changes in tax laws or exposure to additional income tax liabilities could have a material impact on LivaNova’s results of operations and financial condition
3. 28As a public limited company incorporated under the laws of England and Wales, certain of LivaNova’s capital structure decisions require shareholder approval, which may limit the Company’s flexibility to manage its capital structure
4. 29Transfers of LivaNova’s shares, other than those effected by means of the transfer of book-entry interests in DTC, may be subject to UK Stamp Duty or SDRT
5. 30The transferee generally pays the UK stamp duty or SDRT, although the position may be different in the case of a transfer to a depository or into a clearance service. The potential for UK stamp duty or SDRT could adversely affect the trading price of LivaNova’s shares